懒惰的B细胞非何杰金淋巴瘤（B-NHL）是一组异质的淋巴增生性疾病，其特征为生长缓慢和反复发作。直到最近，管理方式在所有懒惰的B-NHL亚型中一直是统一的。对每种疾病的病理生理和分子特征的改进促使开发了多种靶向治疗方法。因此，现在必须将每种亚型视为独立的实体。在本文中，我们考虑了三种常见的懒惰B-NHL：滤泡性淋巴瘤、边缘区淋巴瘤和华氏巨球蛋白血症，并详细评价了每种B-NHL亚型的批准和新兴靶向治疗药物的数据。版权所有©2023 Elsevier Ltd.。保留所有权利。

The indolent B-cell non-Hodgkin lymphomas (B-NHL) comprise a heterogenous group of lymphoproliferative disorders characterized by slow growth kinetics and a relapsing/remitting course. Management has, until recently, been uniform across all indolent B-NHL subtypes. Improving insight into pathophysiological and molecular features of each disease has led to development of several targeted therapies. Consequently, each subtype must now be considered an individual entity. In this review, we consider the three commonest indolent B-NHLs: follicular lymphoma, marginal zone lymphoma and Waldenstrom's macroglobulinemia and review in detail the data on approved and emerging targeted therapeutic agents for each B-NHL subtype.Copyright © 2023 Elsevier Ltd. All rights reserved.